Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 654Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 4Bristol-Myers Squibb Canada

filter clear-filterReset all filters

filter clear-filterReset all filters

filter clear-filterReset all filters

filter clear-filterReset all filters

PharmaCompass

01

arrow
2024 ACI Convention
Not Confirmed
arrow
2024 ACI Convention
Not Confirmed

Daclatasvir

Brand Name : DAKLINZA

Patent Number : 2660520

Filing Date : 2007-08-09

Strength per Unit : 30 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2027-08-09

Date Granted : 2015-01-13

blank

02

arrow
2024 ACI Convention
Not Confirmed
arrow
2024 ACI Convention
Not Confirmed

Daclatasvir

Brand Name : DAKLINZA

Patent Number : 2695729

Filing Date : 2008-07-31

Strength per Unit : 30 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2028-07-31

Date Granted : 2015-03-31

blank

03

arrow
2024 ACI Convention
Not Confirmed
arrow
2024 ACI Convention
Not Confirmed

Daclatasvir

Brand Name : DAKLINZA

Patent Number : 2695729

Filing Date : 2008-07-31

Strength per Unit : 60 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2028-07-31

Date Granted : 2015-03-31

blank

04

arrow
2024 ACI Convention
Not Confirmed
arrow
2024 ACI Convention
Not Confirmed

Daclatasvir

Brand Name : DAKLINZA

Patent Number : 2660520

Filing Date : 2007-08-09

Strength per Unit : 60 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2027-08-09

Date Granted : 2015-01-13

blank